Abstract
Background The role of nutritional status and risk for contracting and/or suffering adverse outcomes from SARS-CoV-2 infection is unclear. Preliminary studies suggest that higher n-3 PUFA intakes may be protective.
Objectives The purpose of this study was to compare risk for three COVID-19 outcomes (testing positive for SARS-CoV-2, hospitalization, and death) as a function of baseline plasma DHA levels.
Methods DHA levels (% of total fatty acids) were measured by nuclear magnetic resonance. The three outcomes and relevant covariates were available for 110,584 subjects (hospitalization and death) and for 26,595 ever-tested subjects (positive for SARS-CoV-2) in the UK Biobank prospective cohort study. Outcome data between January 1, 2020 and March 23, 2021 were included. Omega-3 Index (red blood cell EPA+DHA%) values across DHA% quintiles were estimated. Multi-variable Cox-proportional hazards models were constructed and linear (per 1-SD) relations with risk for each outcome were computed as hazard ratios (HRs).
Results In the fully adjusted models, comparing the fifth to the first DHA% quintiles, the HR for testing positive (95% CI) was 0.79 (0.71, 0.89; p<0.001), for being hospitalized was 0.74 (0.58, 0.94; P<0.05), and for dying with COVID-19 was 1.04 (0.69, 1.57; NS). On a per 1-SD increase in DHA% basis, the HRs were: for testing positive, 0.92 (0.89,0.96; p<0.001); for hospitalization, 0.89 (0.83, 0.97; p<0.01); and for death, 0.95 (0.83,1.09). Estimated Omega-3 Index values across DHA quintiles ranged from 3.5% (quintile 1) to 8% (quintile 5).
Conclusions These findings suggest that nutritional strategies to increase circulating n-3 PUFA levels, such as increased consumption of oily fish and/or use of n-3 fatty acid supplements, may reduce risk for adverse COVID-19 outcomes.
Competing Interest Statement
WSH holds stock in OmegaQuant Analytics, LLC, a laboratory that offers blood fatty acid testing (including the Omega-3 Index) for researchers, clinicians and consumers.
Funding Statement
This analysis was supported in part by the William H. Donner Foundation which played no role in any aspect of this investigation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank has ethical approval (Ref. 11/NW/0382) from the North West Multi-centre Research Ethics Committee as a Research Tissue Bank.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Sources of Support: This analysis was supported in part by the William H. Donner Foundation which played no role in any aspect of this investigation.
Conflict of Interest: WSH holds stock in OmegaQuant Analytics, LLC, a laboratory that offers blood fatty acid testing (including the Omega-3 Index) for researchers, clinicians and consumers. NLT, SPS and JW have nothing to disclose.
William Harris is a member of the Journal’s Editorial Board
Some minor typos have been corrected.
Data Availability
Codebook and analytic code related to data described in the manuscript will be made available upon reasonable request pending application to and approval by the Fatty Acid Research Institute. Raw data are available via standard application procedures directly from the UKbiobank.
Abbreviations
- CI
- confidence interval
- eO3I
- estimated Omega-3 Index (erythrocyte EPA+DHA%)
- HR
- hazard ratio
